Vaccine therapy for renal cancer

References

• Godley PA, Taylor M. Renal cell carcinoma. Curr. Opin. Oncol.13, 199–203 (2001).
   PubMed Web of Science ®Google Scholar
• Amato RJ. Chemotherapy for renal cell carcinoma. Semin. Oncol.27, 177–186 (2000).
   PubMed Web of Science ®Google Scholar
• Bukowski RM. Cytokine therapy for metastatic renal cell carcinoma. Semin. Urol. Oncol.19, 148–154 (2001).
   PubMedGoogle Scholar
• Ritossa FA. New puffing pattern induced by temperature shock and DNP in Drosophilia. Experientia18, 571–573 (1962).
   Google Scholar
• Srivastava PK. Immunotherapy for human cancer using heat shock protein–peptide complexes. Curr. Oncol. Rep.7, 104–108 (2005).
   PubMedGoogle Scholar
• Zhu X, Zhao X, Burkholder WF et al. Structural analysis of substrate binding by the molecular chaperone DnaK. Science272, 1606–1614 (1996).
   PubMed Web of Science ®Google Scholar
• Macary PA, Javid B, Floto RA et al. HSP70 peptide binding mutants separate antigen delivery from dendritic cell stimulation. Immunity20, 95–106 (2004).
   PubMed Web of Science ®Google Scholar
• Linderoth NA, Popowicz A, Sastry, S. Identification of the peptide-binding site in the heat shock chaperone/tumor rejection antigen GP96 (Grp94). J. Biol. Chem.272, 5472–5477 (2000).
   Google Scholar
• Baker-Lepain JC, Saarzotti M, Fields TA, Li CY, Nicchitta CV. GRP94 (GP96) and GRP94 N-terminal geldanamycin binding domain elicit tissue nonrestricted tumor suppression. J. Exp. Med.196, 1447–1459 (2002).
   PubMed Web of Science ®Google Scholar
• Gidalevitz T, Biswas C, Ding H et al. Identification of the N-terminal peptide binding site of glucose-regulated protein 94. J. Biol. Chem.279, 16543–16552 (2004).
   PubMed Web of Science ®Google Scholar
• Goetz MP, Toft DO, Ames MM et al. The HSP90 chaperone complex as a novel target for cancer therapy. Ann. Oncol.14, 1169–1176 (2003).
   PubMed Web of Science ®Google Scholar
• Ishii T, Udono H, Yamano T et al. Isolation of MHC class I-restricted tumor antigen peptide and its precursors associated with heat shock proteins HSP70, HSP90, and GP96. J. Immunol.162, 1303–1309 (1999).
   PubMed Web of Science ®Google Scholar
• Sponaas AM, Zuegel U, Weber S et al. Immunization with GP96 from Listeria monocytogenes-infected mice is due to N-formylated listerial peptides. J. Immunol.167, 6480–6486 (2001).
   PubMed Web of Science ®Google Scholar
• Meng SD, Song J, Rao Z et al. Three-step purification of GP96 from human liver tumor tissues suitable for isolation of GP96-bound peptides. J. Immunol. Methods264, 29–35 (2002).
   PubMed Web of Science ®Google Scholar
• Grossmann ME, Madden BJ, Gao F et al. Proteomics shows Hsp70 does not bind peptide sequences indiscriminately in vivo. Exp. Cell Res.297, 108–117 (2004).
   PubMed Web of Science ®Google Scholar
• Demine R, Walden P. Testing the role of GP96 as peptide chaperone in antigen processing. J. Biol. Chem.280, 17573–17578 (2005).
   PubMed Web of Science ®Google Scholar
• Srivastava P. Interaction of heat shock proteins with peptides and antigen presenting cells: chaperoning of the innate and adaptive immune responses. Annu. Rev. Immunol.20, 395–425 (2002).
   PubMed Web of Science ®Google Scholar
• Przepiorka D, Srivastava PK. Heat shock protein–peptide complexes as immunotherapy for human cancer. Mol. Med. Today.4, 478–484 (1998).
   PubMedGoogle Scholar
• Srivastava PK, Amato RJ. Heat shock proteins: the “Swiss Army knife” vaccines against cancers and infectious agents. Vaccine19, 590–2597 (2001).
   Google Scholar
• Srivastava P. Roles of heat shock proteins in innate and adaptive immunity. Nat. Rev. Immunol.2, 185–194 (2002).
   PubMed Web of Science ®Google Scholar
• Binder RJ, Han DK, Srivastava PK. CD91: a receptor for heat shock protein GP96. Nat. Immunol.1, 151–155 (2000).
   PubMed Web of Science ®Google Scholar
• Basu S, Binder RJ, Ramalingam T, Srivastava PK. CD91 is a common receptor for heat shock proteins GP96, HSP90, HSP70, and calreticulin. Immunity14, 303–313 (2001).
   PubMed Web of Science ®Google Scholar
• Banerjee PP, Vinay DS, Mathew A et al. Evidence that glycoprotein 96 (B2), a stress protein, functions as a Th2-specific costimulatory molecule. J. Immunol.169, 3507–3518 (2002).
   PubMed Web of Science ®Google Scholar
• Binder RJ, Srivastava PK. Essential role of CD91 in re-presentation of GP96-chaperoned peptides. Proc. Natl Acad. Sci. USA101, 6128–6133 (2004).
   PubMed Web of Science ®Google Scholar
• Park JE, Facciponte J, Chen X et al. Chaperoning function of stress protein grp170, a member of the HSP70 superfamily, is responsible for its immunoadjuvant activity. Cancer Res.66, 1161–1168 (2006).
   PubMed Web of Science ®Google Scholar
• Kim HL, Sun X, Subjeck JR, Wang XY. Evaluation of renal cell carcinoma vaccines targeting carbonic anhydrase IX using heat shock protein 110. Cancer Immunol. Immunother.56, 1097–1105 (2007).
   PubMed Web of Science ®Google Scholar
• Li Y, Subjeck J, Yang G, Repasky E et al. Generation of anti-tumor immunity using mammalian heat shock protein 70 DNA vaccines for cancer immunotherapy. Vaccine24, 5360–5370 (2006).
   PubMed Web of Science ®Google Scholar
• Gomez-Gutierrez JG, Elpek KG et al. Vaccination with an adenoviral vector expressing calreticulin–human papillomavirus 16 E7 fusion protein eradicates E7 expressing established tumors in mice. Cancer Immunol. Immunother.56, 997–1007 (2007).
   PubMed Web of Science ®Google Scholar
• Strbo N, Yamazaki K, Lee K. Heat shock fusion protein GP96-Ig mediates strong CD8 CTL expansion in vivo. Am. J. Reprod. Immunol.48, 220–225 (2002).
   PubMed Web of Science ®Google Scholar
• Sengupta D, Norris PJ, Suscovich TJ et al. Heat shock protein-mediated cross-presentation of exogenous HIV antigen on HLA class I and class II. J. Immunol.173, 1987–1993 (2004).
   PubMed Web of Science ®Google Scholar
• Doody AD, Kovalchin JT, Mihalyo MA et al. Glycoprotein 96 can chaperone both MHC class I- and class II-restricted epitopes for in vivo presentation, but selectively primes CD8+ T-cell effector function. J. Immunol.172, 6087–6092 (2004).
   PubMed Web of Science ®Google Scholar
• Rapp UK, Kaufmann SH. DNA vaccination with GP96-peptide fusion proteins induces protection against an intracellular bacterial pathogen. Int. Immunol.16, 597–605 (2004).
   PubMed Web of Science ®Google Scholar
• Tamura Y, Peng P, Liu K, Daou M, Srivastava PK. Immunotherapy of tumors with autologous tumor-derived heat shock protein preparations. Science278, 117–120 (1997).
   PubMed Web of Science ®Google Scholar
• Parmiani G, Testori A, Maio M et al. Heat shock proteins and their use as anticancer vaccines. Clin. Cancer Res.10, 8142–8146 (2004).
   PubMed Web of Science ®Google Scholar
• Janetzki S, Palla D, Rosenhauer V. Immunization of cancer patients with autologous cancer-derived heat shock protein GP96 preparations: a pilot study. Int. J. Cancer.88, 232–238 (2000).
   PubMed Web of Science ®Google Scholar
• Amato R, Murray L, Wood L et al. Active specific immunotherapy in patients with renal cell carcinoma (RCC) using autologous tumor derived heat shock protein–peptide complex-96 (HSPP-96) vaccine. Proc. Am. Soc. Clin. Oncol.18, 322a (1999).
   Google Scholar
• Assikis VJ, Dallani D, Pagliaro L et al. Phase II study of an autologous tumor derived heat shock protein–peptide complex vaccine (HSPPC-96) for patients with metastatic renal cell carcinoma (mRCC). Proc. Am. Soc. Clin. Oncol.22, 386 (2003).
   Google Scholar
• Wood CG, Escudier B, Lacombe L et al. A multicenter randomized Phase 3 trial of a novel autologous therapeutic vaccine (vitespen) vs observation adjuvant therapy in patients at high-risk of recurrence after nephrectomy for renal cell carcinoma (RCC). Proceedings of the AUA Annual Meeting Program Abstracts177, 212 (2007).
   Google Scholar
• Harrop R, John J, Carroll MW. Recombinant viral vectors: cancer vaccines. Adv. Drug Deliv. Rev.58, 931–947 (2006).
   PubMed Web of Science ®Google Scholar
• Harrop R, Carroll MW. Viral vectors for cancer immunotherapy. Frontiers in Bioscience11, 804–817 (2006).
   PubMed Web of Science ®Google Scholar
• Hole N, Stern PL. A 72 kD trophoblast glycoprotein defined by a monoclonal antibody. Br. J. Cancer57, 237–246 (1988).
   Web of Science ®Google Scholar
• Southall P, Boxer G, Bagshaw K et al. Immunological distribution of 5T4 antigen in normal and malignant tissues. Br. J. Cancer61, 89–95 (1990).
   PubMed Web of Science ®Google Scholar
• Starzynska T, Marsh P, Schofield P et al. Prognostic significance of 5T4 oncofoetal antigen expression in colorectal carcinoma. Br. J. Cancer69, 899–902 (1994).
   PubMed Web of Science ®Google Scholar
• Griffiths RW, Gilham DE, Dangoor A et al. Expression of the 5T4 oncofoetal antigen in renal cell carcinoma: a potential target for T-cell-based immunotherapy. Br. J. Cancer93, 670–677 (2005).
   PubMed Web of Science ®Google Scholar
• Barrow KM, Ward CM, Rutter J. Embryonic expression of murine 5T4 oncofoetal antigen is associated with morphogenetic events at implantation and in developing epithelia. Dev. Dyn.233, 1535–1545 (2005).
   PubMed Web of Science ®Google Scholar
• Carsberg C, Myers KA, Stern PL. Metastasis-associated 5T4 antigen disrupts cell–cell contacts and induces cellular motility in ephithelial cells. Int. J. Cancer68, 84–92 (1996).
   PubMed Web of Science ®Google Scholar
• Carroll MW, Restifo NP. Poxviruses as vectors for cancer immunotherapy. In: Cancer Vaccines and Immunotherapy. Stern PL et al. (Eds). Cambridge University Press, Cambridge, UK 47–65 (2000).
   Google Scholar
• Sutter G, Moss B. Non-replicating vaccinia vector efficiently expresses recombinant genes. Proc. Natl Acad. Sci. USA89, 10847–10851 (1992).
   PubMed Web of Science ®Google Scholar
• Rochlitz C, Figlin R, Squiban P et al. Phase I immunotherapy with a modified vaccinia virus (MVA) expressing human MUC1 as antigen-specific immunotherapy in patients with MUC1-positive advanced cancer. J. Gene Med.5, 690–699 (2003).
   PubMed Web of Science ®Google Scholar
• Eder J, Kantoff P, Roper K et al. A Phase I trial of a recombinant vaccinia virus expressing prostate-specific antigen in advanced prostate cancer. Clin. Cancer Res.6, 1632–1638 (2000).
   PubMed Web of Science ®Google Scholar
• Marshall J, Hoyer R, Toomey M et al. Phase I study in advanced cancer patients of a diversified prime-and-boost vaccination protocol using recombinant vaccinia virus and recombinant nonreplicating avipox virus to elicit anti-carcinoembryonic antigen immune responses. J. Clin. Oncol.18, 3964–3973 (2000).
   PubMed Web of Science ®Google Scholar
• Harrop R, Ryan M. Active treatment of murine tumors with a highly attenuated vaccinia virus expressing the tumor associated antigen 5T4 (TroVax) is CD4+ T-cell dependent and antibody mediated. Cancer Immunol. Immunother.55, 1081–1090 (2006).
   PubMed Web of Science ®Google Scholar
• Mulryan K, Ryan MG, Myers KA et al. Attenuated recombinant vaccinia virus expressing oncofetal antigen (tumor-associated antigen) 5T4 induces active therapy of established tumors. Mol. Cancer Ther.1, 1129–1137 (2002).
   PubMed Web of Science ®Google Scholar
• Redchenko I, Harrop R, Ryan MG et al. Identification of a major histocompatibility complex class I-restricted epitope in the tumour-associated antigen, 5T4. Immunology118, 50–57 (2006).
   PubMed Web of Science ®Google Scholar
• Harrop R, Connolly NB, Redchenko I et al. Vaccination of colorectal cancer patients with modified vaccinia Ankara delivering the tumor antigen 5T4 (TroVax) induces immune responses which correlate with disease control: a Phase I/II Trial. Clin. Cancer Res.12, 3416–3424 (2006).
   PubMed Web of Science ®Google Scholar
• Harrop R, Drury N, Shingler W et al. Vaccination of colorectal cancer patients with modified vaccinia Ankara encoding the tumor antigen 5T4 (TroVax) given alongside chemotherapy induces potent immune responses. 57(7), 977–986 (2008).
   Google Scholar
• Harrop R, Hawkins RE, Anthoney A et al. An open label Phase II study of modified vaccinia Ankara (MVA) expressing the tumor antigen 5T4 given in conjunction with chemotherapy: safety and immunogenicity before, during and after chemotherapy. Proceedings of the 2005 ASCO Annual Meeting23, 2578 (2005).
   Google Scholar
• Dangoor A, Burt D, Harrop R et al. A vaccinia-based vaccine (TroVax) targeting the oncofetal antigen 5T4 administered before and after surgical resection of colorectal cancer liver metastases: Phase II trial. Proceedings of the 2006 ASCO Annual Meeting24, 2574 (2006).
   Google Scholar
• Kaufman HL, Deraffele G, Mitcham J et al. A Phase I clinical trial of MVA expressing 5T4 and high-dose interleukin-2 (IL-2) for metastatic renal cell carcinoma. Proceedings of the 2006 ASCO Annual Meeting Proceedings Part I24, 12500 (2006).
   Google Scholar
• Cao A, Hernandez-McClain J, Willis J et al. Activity of MVA 5T4 alone or in combination with either interleukin-2, interferon-a in patients with metastatic renal cell cancer. Proceedings of the 2007 ASCO Annual Meeting25, 135s (2007).
   Google Scholar
• Amato R, Karediy M, Cao A et al. Phase II trial to assess the activity of MVA 5T4 (TroVax) alone versus MVA 5T4 plus granulocyte macrophage colony-stimulating factor in patients with progressive hormone refractory prostate cancer. Proceedings of the 2007 ASCO Annual Meeting25, 241s (2007)
   Google Scholar
• Motzer R, Mazumdar M, Bacik J et al. Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J. Clin. Oncol.17, 2530–2540 (1999)
   PubMed Web of Science ®Google Scholar
• Yang J, Sherry R, Steinberg S et al. Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cell cancer. J. Clin. Oncol.21, 3127–3132 (2003).
   PubMed Web of Science ®Google Scholar
• Höltl L, Rieser C, Papesh C et al. Cellular and humoral immune responses in patients with metastatic renal cell carcinoma after vaccination with antigen pulsed dendritic cells. J. Urol.161, 777–82 (1999).
   PubMed Web of Science ®Google Scholar
• Rieser C, Ramoner R, Holtl L et al. Mature dendritic cells induce T-helper type-1-dominant immune responses in patients with metastatic renal cell carcinoma. Urol. Int.63, 151–159 (2000).
   Web of Science ®Google Scholar
• Kugler A, Stuhler G, Walden P et al. Regression of human metastatic renal cell carcinoma after vaccination with tumor cell-dendritic cell hybrids. Nat. Med.6, 332–336 (2000).
   PubMed Web of Science ®Google Scholar
• Chang AE, Li Q, Jiang G et al. A Phase II trial of anti-CD3 activated,vaccine-primed lymphocytes in stage IV renal cell cancer. Proc. Am. Soc. Clin. Oncol.21, 3a (2002).
   Google Scholar
• Gurjal A, Dansey RD, Klein JL et al. Phase II trial of specific cellular immunotherapy in renal cell carcinoma (RCC). Proc. Am. Soc. Clin. Oncol.20, 222b (2001).
   Google Scholar
• Doehn C, Richter A, Lehmacher W et al. Multicenter Phase III trial to compare radical nephrectomy plus adjuvant autologous tumor cell-lysate vaccine versus radical nephrectomy without adjuvant treatment for renal cell carcinoma stages pT2–3bpN0–3m0: a 3 year analysis. Proc. Am. Soc. Clin. Oncol.21, 180a (2002).
   Google Scholar
• Galligioni E, Quaia M, Merlo A et al. Adjuvant immunotherapy treatment of renal carcinoma patients with autologous tumor cells and bacilus Calmette–Guerin: five-year results of a prospective randomized study. Cancer77, 2560–2566 (1996).
   PubMed Web of Science ®Google Scholar
• Dillman RO, Barth NM, VanderMolen LA et al. Treatment of kidney cancer with autologous tumor cell vaccines of short-term cell lines derived from renal cell carcinoma. Cancer Biother. Radiopharm.16, 47–54 (2001).
   Google Scholar
• Dudek AZ, Mescher MF, Okazaki I et al. Autologous large multivalent immunogen vaccine in patients with metastatic melanoma and renal cell carcinoma. Am. J. Clin. Oncol.31, 173–181 (2008).
   PubMedGoogle Scholar
• Fishman M, Hunter TB, Soliman H et al. Phase II trial of B7–1 (CD-86) transduced, cultured autologous tumor cell vaccine plus subcutaneous interleukin-2 for treatment of stage IV renal cell carcinoma. J. Immunother.31, 72–80 (2008)
   PubMedGoogle Scholar
• Desai J, Mithcell P, Loveland B et al. A Phase I trial of dendritic cells pulsed with MUC1 peptide in patients with solid tumors. Proc. Am. Soc. Clin. Oncol.21, 15b (2002).
   Google Scholar
• Vissers JLM, De Vries JM, Schreurs MWJ et al. The renal cell carcinoma-associated antigen G250 encodes a human leukocyte antigen (HLA)-A2.1-restricted epitope recognized by cytotoxic T lymphocytes. Cancer Res.59, 5554–5559 (1999).
   PubMed Web of Science ®Google Scholar
• Tso C-L, Zisman A, Pantuck A et al. Induction of G250-targeted and T-cell-mediated antitumor activity against renal cell carcinoma using a chimeric fusion protein consisting of G250 and granulocyte/monocyte-colony stimulating factor. Cancer Res.61, 7925–7933 (2001).
   PubMed Web of Science ®Google Scholar
• Hsu FJ, Komarovskaya M. Idiotype-specific T-cell activation/amplification using CTLA4 blockade and targeting of tumor to dendritic cells. Proc. Am. Soc. Clin. Oncol.21, 25a (2002).
   Google Scholar
• Okazaki I, Mescher M, Curtsinger J et al. An autologous large multivalent immunogen (LMI) vaccine for the treatment of metastatic melanoma and renal cell carcinoma. Proc. Am. Soc. Clin. Oncol.21, 20a (2002).
   Google Scholar
• Avigan DE, Vasir B, George DJ et al. Phase I/II study of vaccination with electrofused allogeneic dendritic cells/autologous tumor-derived cells in patients with stage IV renal cell carcinoma. J. Immunother.30, 749–761 (2007).
   PubMed Web of Science ®Google Scholar
• Bleumer I, Tiemessen DM, Oosterwijk-Wakka JC et al. Preliminary analysis of patients with progressive renal cell carcinoma vaccinated with CA9-peptide-pulsed mature dendritic cells. J. Immunother.30, 116–122 (2007).
   PubMed Web of Science ®Google Scholar
• Ishii T, Udono H, Yamano T et al. Isolation of MHC Class I-restricted tumor antigen peptide and its precursors associated with heat shock proteins hsp70, hsp90, and gp96. J. Immunol.162, 1303–1309 (1999).
   PubMed Web of Science ®Google Scholar
• Castelli C, Ciupitu A-M, Rini F et al. Human heat shock protein 70 peptide complexes specifically activate antimelanoma T cells. Cancer Res.61, 222–227 (2001).
   PubMed Web of Science ®Google Scholar
• Belli F, Testori A, Rivoltini L et al. Vaccination of metastatic melanoma patients with autologous tumor-derived heat shock protein GP96-peptide complexes: clinical and immunologic findings. J. Clin. Oncol.20, 4169–4180 (2002).
   PubMed Web of Science ®Google Scholar
• Richards J, Testori A, Whitman E et al. Autologous tumor-derived HSPPC-96 vs. physician’s choice (PC) in a randomized Phase III trial in stage IV melanoma. 2006 ASCO Annual Meeting Proceedings, Atlanta, USA 2006 (Abstract 8002).
   Google Scholar
• Pilla L, Patuzzo R, Rivoltini L et al. A Phase II trial of vaccination with autologous, tumor-derived heat shock protein peptide complexes GP96, in combination with GM-CSF and interferon-α in metastatic melanoma patients. Cancer. Immunol. Immunother.55, 958–968 (2006).
   PubMed Web of Science ®Google Scholar
• Mazzaferro V, Coppa J, Carrabba MG et al. Vaccination with autologous tumor-derived heat shock protein GP96 after liver resection for metastatic colorectal cancer. Clin. Cancer Res.9, 3235–3245 (2003).
   PubMed Web of Science ®Google Scholar